Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Carisma Therapeutics Inc.SESN · Entity 74418 | Principal Accounting Officer | March 02, 2023 | March 06, 2023 |
| Firy Inc.SKLZ · Entity 6462 | Controller/Head of Accounting | July 05, 2023 | July 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Carisma Therapeutics Inc.
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 148,624 |
Reported balance
After 2023-03-02 transaction · row 1
1 source rowRow 1 · 2023-03-02 · Sale · Disposed 17,289 · Balance 148,624 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the price set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the price set forth above.
Firy Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,308 |
Reported balance
After 2023-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 5,308 · Balance 5,308 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A common stock. F2: On June 23, 2023, the Issuer completed a 1-for-20 reverse stock split (the "Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3: 100% of the restricted stock unit grant will vest on April 3, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A common stock.
F2: On June 23, 2023, the Issuer completed a 1-for-20 reverse stock split (the "Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split.
F3: 100% of the restricted stock unit grant will vest on April 3, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2023 Filed Jul 7, 2023 16:20 UTC | Firy Inc. SKLZ · Entity 6462 | GrantRestricted Stock Units · Derivative | 5,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001860740-23-000005 · wf-form4_168876122944669.xml · derivative · entry 1 Ryu Elly · CIK 0001860740 · Controller/Head of Accounting 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,308 Underlying: Class A common stock · 5,308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A common stock. F2 · shares: On June 23, 2023, the Issuer completed a 1-for-20 reverse stock split (the "Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3 · derivative.exercise_date: 100% of the restricted stock unit grant will vest on April 3, 2024. F3 · derivative.expiration_date: 100% of the restricted stock unit grant will vest on April 3, 2024. F2 · derivative.underlying_shares: On June 23, 2023, the Issuer completed a 1-for-20 reverse stock split (the "Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F2 · balance_after: On June 23, 2023, the Issuer completed a 1-for-20 reverse stock split (the "Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 20:44 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | SaleCommon Stock | 17,289 | $0.59 | $10,148.64 |
DisclosureSEC source: 0001485003-23-000108 · wf-form4_167815347664943.xml · nonDerivative · entry 1 Ryu Elly · CIK 0001860740 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,624 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022, which vested in connection the approval by Issuer's shareholders of the reverse merger transaction between the Issuer and Carisma Therapeutics, Inc. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the price set forth above. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 19:36 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | SaleCommon Stock | 7,159 | $0.59 | $4,204.48 |
DisclosureSEC source: 0001485003-23-000064 · wf-form4_167719898027733.xml · nonDerivative · entry 1 Ryu Elly · CIK 0001860740 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,913 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of shares of common stock pursuant to a restricted stock unit award granted on February 18, 2022. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The Reporting Person hereby undertakes to provide, upon request, to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at the price set forth above. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 19:22 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantEmployee Stock Option (Right to Buy) · Derivative | 95,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001485003-22-000070 · wf-form4_165429852663606.xml · derivative · entry 1 Ryu Elly · CIK 0001860740 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,500 Underlying: Common Stock · 95,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: On June 1, 2022, the reporting person was awarded options to purchase 95,500 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vest date. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 20:37 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantCommon Stock | 86,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001485003-22-000021 · wf-form4_164566659718713.xml · nonDerivative · entry 1 Ryu Elly · CIK 0001860740 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,300 F1 · shares: Represents restricted stock units ("RSUs") which shall vest annually in equal amounts over a four-year period following the grant date, so long as the reporting person remains employed by Sesen Bio, Inc.(the "Company"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 19:29 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001485003-21-000196 · wf-form4_163339016370662.xml · nonDerivative · entry 1 Ryu Elly · CIK 0001860740 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,696 F1 · shares: Represents restricted stock units which vest in full on September 30, 2022, subject to recipient's continued employment through September 30, 2022. Each restricted stock unit represents a contingent right to receive one share of the Sesen Bio, Inc.'s common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.